Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess safety and efficacy of tadalafil in patients with
Sarcoidosis Associated Pulmonary Hypertension.
Hypothesis: Tadalafil is safe and effective in treating pulmonary hypertension in patients
with Sarcoidosis
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Eli Lilly and Company United Therapeutics University of Cincinnati